ArticleNature chemistry2026
Recoding multiple rare codons enables the simultaneous incorporation of up to five distinct noncanonical amino acids.
Article in Nature chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Expanding the genetic code has revolutionized our ability to study and manipulate biological systems through site-specific incorporation of noncanonical amino acids (ncAAs). However, current methods are primarily limited to single-type ncAA incorporation in mammalian cells owing to translation inefficiency. Here we introduce a multi-type rare codon recoding strategy that addresses this limitation. By systematically evaluating and repurposing rare codons, alongside engineering mutually orthogonal aminoacyl-tRNA synthetase/tRNA pairs, we achieve the expression of proteins containing two or three distinct ncAAs at site-specific positions with recoding rates of up to 90% at wild-type protein expression levels in mammalian cells. This approach facilitates a broad range of applications, including dual bioorthogonal labelling and sequential protein activation. We further demonstrate the utility of this strategy by incorporating up to five distinct ncAAs into a single protein, revealing a redefinable nature of the genetic code and opening unprecedented avenues for future applications in biomedicine and synthetic biology.
Indexed as
Identifiers
41826677What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.